IP Library Granted Patent US 10,941,214
Granted Patent B2
US 10,941,214 · App. 16/688,374 · Granted Mar 9, 2021

Compositions and methods comprising histidyl-tRNA synthetase splice variants having non-canonical biological activities

Inventors: Jie Zhou (Hong Kong, CN); Ching-Fun Lau (Hong Kong, CN); Zhiwen Xu (Hong Kong, CN); Wing-Sze Lo (Hong Kong, CN); Kristi Helen Piehl (San Diego, CA); Leslie Ann Greene (San Diego, CA)
Assignees: aTyr Pharma, Inc.; Paneu BioPharma Limited
C07K16/40C12N9/93C12N15/1137C12Q1/6876C12Q1/6886C12Y601/01021G01N33/573A61K38/00C07K2317/24C07K2317/56C07K2317/622C07K2317/76C12N2310/11C12N2310/14C12Q2600/136C12Q2600/156G01N2333/9015G01N2500/04G01N2500/10
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,941,214
App. No.
16/688,374
Granted
Mar 9, 2021
Kind
B2
Abstract

Isolated histidyl-tRNA synthetase splice variant polynucleotides and polypeptides having non-canonical biological activities are provided, as well as compositions and methods related thereto.

Claims (4)

1. An intranasal spray, or an inhalation or aerosol delivery vehicle, comprising a physiologically acceptable carrier and a fusion polypeptide, wherein the fusion polypeptide comprises a histidyl-tRNA synthetase (HRS) polypeptide fused to an Fc fragment, wherein the HRS polypeptide consists of a sequence that has at least 95% identity along its length to SEQ ID NO: 6, comprises a WHEP domain, and lacks a functional aminoacylation domain.

2. The intranasal spray, or an inhalation or aerosol delivery vehicle, of claim 1 , wherein the HRS polypeptide consists of a sequence that has at least 98% identity along its length to SEQ ID NO: 6.

3. The intranasal spray, or an inhalation or aerosol delivery vehicle, of claim 1 , wherein the N-terminal region of the HRS reference polypeptide is truncated by 1, 2, or 3 amino acids.

4. A method of delivering a fusion polypeptide composition directly to lungs, comprising administering to a subject the intranasal spray, or inhalation or aerosol delivery vehicle, of any one of claims 1 - 3 .

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 18, 2020
From: ZHOU, JIE; LAU, CHING FUN; XU, ZHIWEN; LO, WING SZE; PIEHL, KRISTI HELEN; GREENE, LESLIE ANN
To: ATYR PHARMA, INC.
Reel/Frame 052687/0628 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 18, 2020
From: PANGU BIOPHARMA LIMITED
To: ATYR PHARMA, INC.
Reel/Frame 052688/0283 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 18, 2020
From: ZHOU, JIE; LAU, CHING FUN; XU, ZHIWEN; LO, WING SZE
To: PANGU BIOPHARMA LIMITED
Reel/Frame 052688/0319 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 18, 2020
From: ATYR PHARMA, INC.
To: PANGU BIOPHARMA LIMITED
Reel/Frame 052688/0651 →
Continuity (8)
Continuation 16005045 · Jun 11, 2018
Continuation 15257353 · Sep 6, 2016
Continuation 14262272 · Apr 25, 2014
Continuation 13766659 · Feb 13, 2013
Continuation 12725272 · Mar 16, 2010
Provisional Application 61239747 · Sep 3, 2009
Provisional Application 61160630 · Mar 16, 2009
Related Publication 20200216564A1 · Jul 9, 2020
Cited By (2)
US 12,492,392 US 12,497,466